Advanced search
Publication Cover
OncoImmunology Volume 10, 2021 - Issue 1
Submit an article Journal homepage
1,660
Views
6
CrossRef citations to date
0
Altmetric
Author’s View

An independent predictor of poor prognosis in locally advanced rectal cancer: rs867228 in formyl peptide receptor 1 (FPR1)

Shu-Fen Chianga Laboratory of Precision Medicine, Ministry of Health & Welfare Feng Yuan Hospital, Taichung, TaiwanORCID Iconhttps://orcid.org/0000-0002-0371-2658View further author information
ORCID Icon,
Kevin Chih-Yang Huangb Department of Biomedical Imaging and Radiological Science, China Medical University, Taichung, Taiwan;c Translation Research Core, China Medical University Hospital, China Medical University, Taichung, TaiwanORCID Iconhttps://orcid.org/0000-0002-0266-3233View further author information
ORCID Icon,
William Tzu-Liang Chend Department of Colorectal Surgery, Hsinchu China Medical University Hospital, Hsinchu, Taiwan;e School of Medicine, China Medical University, TaichungTaiwan;f Department of Colorectal Surgery, China Medical University Hospital, China Medical University, Taichung, TaiwanView further author information
,
Tsung-Wei Cheng Graduate Institute of Biomedical Science, China Medical University, Taichung, Taiwan;h Department of Pathology, Asia University Hospital, Asia University, Taichung, TaiwanView further author information
,
Tao-Wei Kef Department of Colorectal Surgery, China Medical University Hospital, China Medical University, Taichung, Taiwan;i School of Chinese Medicine, China Medical University, Taichung, TaiwanCorrespondence[email protected]
View further author information
&
K. S. Clifford Chaoe School of Medicine, China Medical University, TaichungTaiwan;g Graduate Institute of Biomedical Science, China Medical University, Taichung, Taiwan;j Cancer Center, China Medical University Hospital, China Medical University, Taichung, TaiwanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-7162-2566View further author information
ORCID Icon
Article: 1926074 | Received 29 Apr 2021, Accepted 01 May 2021, Published online: 14 May 2021

Figures & data

Figure 1. FPR1 genotype influences antitumor immunity during CCRT treatment in LARC patients. FPR1expresses on DCs and T lymphocytes and participates in DCs and T lymphocytes migration and infiltration and cytotoxic activity. Under CCRT treatment, the CC genotype of FPR1-E346A decreased the recruitment of effector and cytotoxic T lymphocytes within tumor microenvironment to lead to reduce tumor regression and the therapeutic efficacy of CCRT. (created with BioRender.com)

Figure 1. FPR1 genotype influences antitumor immunity during CCRT treatment in LARC patients. FPR1expresses on DCs and T lymphocytes and participates in DCs and T lymphocytes migration and infiltration and cytotoxic activity. Under CCRT treatment, the CC genotype of FPR1-E346A decreased the recruitment of effector and cytotoxic T lymphocytes within tumor microenvironment to lead to reduce tumor regression and the therapeutic efficacy of CCRT. (created with BioRender.com)

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.